- Home
- ATR vs RPRX Comparison
ATR vs RPRX Comparison
Compare ATR & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATR
- RPRX
- Stock Information
- Founded
- ATR 1992
- RPRX 1996
- Country
- ATR United States
- RPRX United States
- Employees
- ATR N/A
- RPRX N/A
- Industry
- ATR Plastic Products
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- ATR Industrials
- RPRX Health Care
- Exchange
- ATR Nasdaq
- RPRX Nasdaq
- Market Cap
- ATR 9.7B
- RPRX 14.4B
- IPO Year
- ATR 1993
- RPRX 2020
- Fundamental
- Price
- ATR $144.80
- RPRX $32.68
- Analyst Decision
- ATR Strong Buy
- RPRX Strong Buy
- Analyst Count
- ATR 5
- RPRX 5
- Target Price
- ATR $183.75
- RPRX $41.60
- AVG Volume (30 Days)
- ATR 405.3K
- RPRX 4.7M
- Earning Date
- ATR 05-01-2025
- RPRX 05-08-2025
- Dividend Yield
- ATR 1.25%
- RPRX 2.69%
- EPS Growth
- ATR 30.12
- RPRX N/A
- EPS
- ATR 5.53
- RPRX 1.91
- Revenue
- ATR $3,582,890,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- ATR $2.82
- RPRX $33.46
- Revenue Next Year
- ATR $5.54
- RPRX $4.44
- P/E Ratio
- ATR $26.18
- RPRX $17.10
- Revenue Growth
- ATR 2.74
- RPRX N/A
- 52 Week Low
- ATR $135.96
- RPRX $24.05
- 52 Week High
- ATR $178.03
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- ATR 39.79
- RPRX 52.33
- Support Level
- ATR $145.14
- RPRX $32.00
- Resistance Level
- ATR $154.00
- RPRX $34.10
- Average True Range (ATR)
- ATR 3.06
- RPRX 0.67
- MACD
- ATR 0.30
- RPRX -0.25
- Stochastic Oscillator
- ATR 10.07
- RPRX 30.91
About ATR AptarGroup Inc.
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. With the bulk of its annual net sales coming from Europe (50% of sales) and the United States (33%), Aptar aims to increase its presence in Asia (10%) and Latin America (7%). It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.